Anti-Rheumatic Drugs - Haiti | Statista Market Forecast

The Anti-Rheumatic Drugs market in Haiti is anticipated to achieve a revenue of US$2.90m in 2024.
With an expected annual growth rate (CAGR 2024-2029) of 0.44%, the market volume is projected to reach US$2.97m by 2029.
In a global perspective, United States is predicted to generate the highest revenue, amounting to US$34.70bn in 2024.
Despite the high prevalence of rheumatic diseases in Haiti, access to anti-rheumatic drugs remains limited, hindering effective management of the condition.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The Anti-Rheumatic Drugs market in Haiti has shown interesting developments in recent years.

Customer preferences: Patients suffering from rheumatoid arthritis and related conditions are the primary customers of anti-rheumatic drugs. In Haiti, like in other parts of the world, the demand for these drugs is increasing due to the growing prevalence of these conditions. Patients in Haiti prefer to use generic drugs due to their affordability.

Trends in the market: The Anti-Rheumatic Drugs market in Haiti has been growing at a steady pace due to the increasing prevalence of rheumatoid arthritis and related conditions. The market has been witnessing a shift towards the use of biologic drugs due to their efficacy in treating these conditions. However, the high cost of biologic drugs has limited their adoption in Haiti. The market for non-steroidal anti-inflammatory drugs (NSAIDs) has been declining due to their side effects and the availability of better alternatives.

Local special circumstances: Haiti is a low-income country with a weak healthcare system. The country has a limited budget for healthcare spending, which has resulted in a lack of access to healthcare facilities and medicines for the majority of the population. The market for anti-rheumatic drugs in Haiti is highly price-sensitive, and affordability is a key factor in determining the demand for these drugs.

Underlying macroeconomic factors: Haiti is one of the poorest countries in the world with a GDP per capita of less than $1,300. The country has been facing political instability and economic challenges in recent years, which has limited its ability to invest in healthcare infrastructure and services. The lack of investment in healthcare has resulted in a shortage of healthcare professionals and facilities, which has limited access to healthcare services for the majority of the population. The high prevalence of rheumatoid arthritis and related conditions in Haiti is a result of poor living conditions, lack of access to healthcare, and limited awareness about these conditions.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.